AbbVie (ABBV): Rep. Josh Gottheimer (NJ05) disclosed a sale $1K–$15K
Rep. Josh Gottheimer (NJ05) disclosed a sale of AbbVie in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 29 days
- Disclosure lag
- Traded
- May 5, 2026
- Disclosed
- Jun 3, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
- Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
- Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
- Mar 6, 2026FDAFDA drug approval: Skyrizi
- Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
- Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
- Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 5, 2026 · this disclosureCongressDisclosed sale of ABBV — reported range $1,001 - $15,000
What came next
- May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
- May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
- May 20, 2026FDAFDA drug approval: Venclexta
- May 21, 2026FDAFDA drug approval: Linzess
- May 27, 2026FDAFDA drug approval: Decnupaz
- Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
- Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Jun 12, 2026FDAFDA drug approval: Skyrizi
- Jun 18, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date
- Jun 26, 2026FDAFDA drug approval: Skyrizi
- Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
- Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
- Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
- Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 14, 2026Insider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market
- Sep 1, 2026Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Sep 2, 2026Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for AbbVie
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.
Other recent filings by Rep. Josh Gottheimer (NJ05)
- House Clerk periodic transaction report at Applied Materials (AMAT)Nov 5, 2026
- House Clerk periodic transaction report at Benchmark Electronics, Inc. (BHE)Nov 5, 2026
- House Clerk periodic transaction report at Perusahaan Perseroan Persero Pt Telekomunikasi Indonesia Tbk (TLK)Nov 5, 2026
- House Clerk periodic transaction report at Applied Materials (AMAT)Oct 7, 2026
- House Clerk periodic transaction report at McDonald's (MCD)Oct 7, 2026
The full history of Rep. Josh Gottheimer (NJ05) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded AbbVie (ABBV) stock, and how much?
Rep. Josh Gottheimer (NJ05) disclosed a sale of AbbVie in the $1K–$15K range. Reported range, not an exact amount, Joint account.
When did it happen, and when was it made public?
Traded: May 5, 2026. Disclosed: Jun 3, 2026. That is 29 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about AbbVie recently?
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.
Does this mean ABBV stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at AbbVie
- SEC Form 144Nov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 9, 2026
- House Clerk periodic transaction reportSep 18, 2026
- SEC Form 13F-HRAug 26, 2026
Everything OQRO holds on this company is on its ABBV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
